Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts
Sarah Haggenmüller(German Cancer Research Center), Mildred Sergon(National Center for Tumor Diseases), Jochen Utikal(German Cancer Research Center), María Teresa Fernández‐Figueras(Universitat Internacional de Catalunya), Bastian Schilling(Goethe University Frankfurt), Catarina Barata(INESC TEC), Lars E. French(University of Miami), Brigid Betz‐Stablein(The University of Queensland), Sebastian Haferkamp(University Hospital Regensburg), Dirk Schadendorf(National Center for Tumor Diseases), Gerardo Ferrara(Azienda Ospedaliera G.Rummo), Friedegund Meier(National Center for Tumor Diseases), Lucie Heinzerling(LMU Klinikum), Mar Llamas‐Velasco(Hospital Universitario de La Princesa), Max Schlaak(Charité - Universitätsmedizin Berlin), Raymond L. Barnhill(Université Paris Cité), Alexander A. Navarini(University Hospital of Basel), Sarah Hobelsberger(National Center for Tumor Diseases), Josep Malvehy(Universitat de Barcelona), Andrea Saggini(Dermatopathologie Friedrichshafen), Omar P. Sangüeza(Wake Forest University), Sebastián Podlipnik(Universitat de Barcelona), Kamran Ghoreschi(National Institutes of Health), Carola Berking(Universitätsklinikum Erlangen), Aimilios Lallas(Aristotle University of Thessaloniki), Achim Hekler(German Cancer Research Center), F. Max Müller, Roman C. Maron(German Cancer Research Center), Pascale Guitera(The University of Sydney), Helmut Beltraminelli(University of Bern), Cristián Navarrete‐Dechent(Pontificia Universidad Católica de Chile), Franz J. Hilke(Charité - Universitätsmedizin Berlin), Carlos Santonja(Hospital Universitario Fundación Jiménez Díaz), Stephan Alexander Braun(Düsseldorf University Hospital), Holger A. Haenssle(Heidelberg University), Antonio Perasole(Ospedale San Bortolo), Markus V. Heppt(Universitätsklinikum Erlangen), Justin Gabriel Schlager(LMU Klinikum), Dieter Krahl, Matthias Goebeler(University of Würzburg), Gabriela Poch(Charité - Universitätsmedizin Berlin), Heinz Kutzner(Dermatopathologie Friedrichshafen), Veronica Rotemberg(Memorial Sloan Kettering Cancer Center), Richard Carr(Warwick Hospital), Marc Combalia, Frank Friedrich Gellrich(National Center for Tumor Diseases), Andreas Blum(Klinikum Konstanz), Sylvie Fraitag(Hôpital Necker-Enfants Malades), Luis Requena(Hospital Universitario Fundación Jiménez Díaz), Konstantinos Liopyris
Cited by 246
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k